Q-omics provides the consensus-scored TVP23CP2 profile across patient tissues and cancer cell-line models. TVP23CP2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, TVP23CP2 is differentially expressed in 4, with the highest sampling consensus in LUSC. Additionally, TVP23CP2 RNA expression shows 7,236 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight STAD, LUSC, and LAML as cancer lineages where TVP23CP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TVP23CP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TVP23CP2 survival associations across molecular data types. TVP23CP2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TVP23CP2 RNA expression–survival associations across cancer types. High TVP23CP2 expression shows unfavorable associations in STAD, DLBC and KIRP, but favorable associations in BRCA, BLCA and KIRC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify STAD as the clearest survival context for TVP23CP2 RNA expression.
This table summarizes TVP23CP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TVP23CP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TVP23CP2 shows lower tumor expression in LUSC, THCA, ESCA and HNSC. The LUSC box plot shows higher TVP23CP2 RNA expression in normal versus tumor tissue (log2 FC = −0.089, t-test p = .006).
This table shows molecular features associated with TVP23CP2 in patient tissues and cancer cell lines. In patient samples, TVP23CP2 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
